But the policy shift is profound: from a market where GLP-1s were a luxury good ($1,000+ per month out of pocket) to a market where millions of seniors have them available at near-cost ($50 copay)
Trn thc t, Glutathione c b sung lm trng da thng dng L-Glutathione
A primary example today is Exondys and Vyondys for Duchennes Muscular Dystrophy which sell $1bn/yr collectively despite limited efficacy
A strong case usually includes BMI data, related health risks, lifestyle efforts, a follow-up plan, and a clear reason the selected medication fits the patients goals and safety needs
A: According to ro.co (pricing as of November 2025), costs include two components: Membership Fees (separate from medication): First month: $45 Subsequent months: $145/month recurring Medication Costs (separate from membership, varies): Zepbound vials (LillyDirect): $349-$499/month Wegovy pens (NovoCare): $499/month Zepbound pens: ~$1,050/month Ozempic: Varies by pharmacy Insurance copay: $25-$300+ (if approved
The shortage rule To understand why compounding pharmacists can make copies of semaglutide (the key ingredient in Ozempic and Wegovy) and tirzepatide (the key ingredient in Mounjaro and Zepbound), you have to understand the shortage rule
